EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Ginsenoside Ro improves Salmonella Typhimurium‐induced colitis through inhibition of the virulence factors SopB and SopE2 via the RAC1 / CDC42 / ARP2 /3 pathway

Xinhua Cui iD, Yang Wang iD, Ziyan Liu iD, Meng Zhao iD, Mingmei Zhu iD, Wanlu Yu iD, Baochun Lu iD, Hongyue Xu iD, Jiajia Liu iD, Ning Liao iD, Jinyang Shi iD, Danping Peng iD und 4 weitere

The FASEB Journal · 2024

DOI: 10.1096/fj.202401712r ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FASEB Journal, 2024. Verfasst von Xinhua Cui und 15 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Key Laboratory for Zoonosis Research of the Ministry of Educ…. Hauptthemen laut MEDLINE: Ginsenosides, Salmonella typhimurium, Colitis, rac1 GTP-Binding Protein. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The National Nature Science Foundation of China, The National Key Research and Development Program of China, The Science and Technology Research Project of the Jilin Provincial Department of Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Salmonella enterica serovar Typhimurium ( S . Typhimurium) poses a serious threat to human and animal health, and there is an urgent need to develop new therapeutic agents. In our in vivo study, ginsenoside Ro (Ro) reduced the mortality rate of S . Typhimurium‐infected mice by effectively improving three key disease activity index (DAI) indicators. In particular, ginsenoside Ro inhibited S . Typhimurium‐induced colitis by reversing colon length shortening; alleviating pathological damage to the colon; decreasing the levels of IL‐1β, TNF‐α, IFN‐γ, and IL‐6; and decreasing the activities of MPO and EPO, while increasing the levels of IL‐10 as well as the colon epithelial barrier and tight junction‐related genes ( Mucin 1 , Mucin 2 , Occludin , Claudin‐3 , and ZO‐1 ). Furthermore, ginsenoside Ro reduced CFUs in the liver, spleen, colon, and feces. In a mechanistic in vitro study, ginsenoside Ro reduced CFUs in HeLa and Raw264.7 cells, which was associated with ginsenoside Ro inhibition of the recruited S. Typhimurium‐containing vacuole (SCV) biomarkers LC3, Rab7, GAL8, and NDP52. Molecular docking results revealed that the binding energies of ginsenoside Ro and SopB and ginsenoside Ro and SopE2 were as high as −11.3 and −9.7 kcal/mol, respectively, as verified by CETSA and DARTS assays. Moreover, ginsenoside Ro at 100 and 200 μM significantly decreased the enzyme activities and expression of SopB and SopE2. Finally, ginsenoside Ro inhibited the membrane ruffling caused by SopB‐regulated Arf6/Cyth2/Arf1‐, RAC1‐, and CDC42‐driven Arp2/3‐dependent actin polymerization and the SopE2‐regulated CDC42/Arp2/3 signaling pathway. In summary, our findings suggest that ginsenoside Ro is a potential lead compound for therapeutic use against S . Typhimurium infection, and these findings lay a foundation for its further development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GinsenosidesSalmonella typhimuriumColitisrac1 GTP-Binding ProteinAnimalsMiceHumansVirulence FactorsSalmonella InfectionsHeLa CellsRAW 264.7 CellsBacterial ProteinsSignal TransductionMalecdc42 GTP-Binding ProteinMice, Inbred C57BL

Stichwörter der Autor:innen

S. Typhimuriumcolitisginsenoside Roinvasionvirulence factors

Substanzen

Ginsenosidesrac1 GTP-Binding ProteinVirulence FactorsBacterial Proteinscdc42 GTP-Binding Protein

Autor:innen und Institutionen

  • State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Key Laboratory for Zoonosis Research of the Ministry of Education, Institute of Zoonosis, College of Veterinary Medicine Jilin Uni…
  • Key Laboratory of Organo-Pharmaceutical Chemistry of Jiangxi Province, Gannan Normal University, Ganzhou, China.

ORCID-Profile: Xinhua Cui, Yang Wang, Ziyan Liu, Meng Zhao, Mingmei Zhu, Wanlu Yu, Baochun Lu, Hongyue Xu, Jiajia Liu, Ning Liao, Jinyang Shi, Danping Peng, Sijia Niu, Jiayi Shen, Jiazhang Qiu, Lu Yu

Förderung

  • The National Nature Science Foundation of China
  • The National Key Research and Development Program of China
  • The Science and Technology Research Project of the Jilin Provincial Department of Education
  • Jilin Provincial Nature Science Foundation of Jilin Provincial Department of Science and Technology
  • MOST | National Natural Science Foundation of China (NSFC)
  • National Key Research and Development Program of China
  • National Natural Science Foundation of China

Zitieren

APA

Cui, X., Wang, Y., Liu, Z., Zhao, M., Zhu, M., Yu, W., Lu, B., Xu, H., Liu, J., Liao, N., Shi, J., Peng, D., Niu, S., Shen, J., Qiu, J., & Yu, L. (2024). Ginsenoside Ro improves Salmonella Typhimurium‐induced colitis through inhibition of the virulence factors SopB and SopE2 via the RAC1 / CDC42 / ARP2 /3 pathway. The FASEB Journal. https://doi.org/10.1096/fj.202401712r

Vancouver

Cui X, Wang Y, Liu Z, Zhao M, Zhu M, Yu W, et al. Ginsenoside Ro improves Salmonella Typhimurium‐induced colitis through inhibition of the virulence factors SopB and SopE2 via the RAC1 / CDC42 / ARP2 /3 pathway. The FASEB Journal. 2024. doi:10.1096/fj.202401712r

BibTeX
@article{Cui2024,
  author = {Cui, Xinhua and Wang, Yang and Liu, Ziyan and Zhao, Meng and Zhu, Mingmei and Yu, Wanlu and Lu, Baochun and Xu, Hongyue and Liu, Jiajia and Liao, Ning and Shi, Jinyang and Peng, Danping and Niu, Sijia and Shen, Jiayi and Qiu, Jiazhang and Yu, Lu},
  title = {Ginsenoside Ro improves Salmonella Typhimurium‐induced colitis through inhibition of the virulence factors SopB and SopE2 via the RAC1 / CDC42 / ARP2 /3 pathway},
  journal = {The FASEB Journal},
  year = {2024},
  doi = {10.1096/fj.202401712r}
}
Kostenlos starten →